[TommY]

Amgen/Boehringer Ingelheim - Information politics

by TommY on Mon Sep 10, 2012 3:20 am

In 2010 Boehringer Ingelheim got into a cooperation with Micromet. BI invested millions to develop a myeloma antibody. Promising news, because the bite technology showed great effects in other blood cancers.

http://www.drugdiscoverynews.com/index.php?newsarticle=3888

Now my point: It's so frustrating, if you are trying to get some information about the status quo of development. The mail I got from BI recently (8/2012) wasn't well written and nearly unpolite. Would be great if companies understand, that an open information politic about develpments is important for their marketing - and our hope. No good job, Boehringer/Amgen. If you are a consultant all people are really polite - if you're a patient - disrespect.

[JulieF]

Boehringer Ingelheim/Amgen; Bite Antibody; Pipeline

by JulieF on Tue Oct 09, 2012 6:00 am

Hi TommY, I can understand your frustration. Anyway - as you I don't know why Amgen and Boehringer do not provide us with more information about their promising approach and research. I think the cooperation is almost dead and Boerhinger Ingelheim and Amgen stopped their research on myeloma items and concentrate themselves on other cancers als AML. My husband is 45 and has myeloma in a refractory stage. We need urgently new agents, that overcome resistance in myeloma. I have read your communication with BI on facebook.Think you can only understand our pressing interest, when you have the disease. Best regards, Julie